GTBIF
Price
$7.56
Change
-$1.07 (-12.40%)
Updated
Aug 15 closing price
Capitalization
1.98B
ORGO
Price
$4.73
Change
+$0.03 (+0.64%)
Updated
Aug 15 closing price
Capitalization
596.23M
81 days until earnings call
Interact to see
Advertisement

GTBIF vs ORGO

Header iconGTBIF vs ORGO Comparison
Open Charts GTBIF vs ORGOBanner chart's image
Green Thumb Industries
Price$7.56
Change-$1.07 (-12.40%)
Volume$1.26M
Capitalization1.98B
Organogenesis Holdings
Price$4.73
Change+$0.03 (+0.64%)
Volume$520.5K
Capitalization596.23M
GTBIF vs ORGO Comparison Chart in %
Loading...
GTBIF
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
ORGO
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
GTBIF vs. ORGO commentary
Aug 17, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is GTBIF is a Hold and ORGO is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Aug 17, 2025
Stock price -- (GTBIF: $8.63 vs. ORGO: $4.70)
Brand notoriety: GTBIF and ORGO are both not notable
Both companies represent the Pharmaceuticals: Generic industry
Current volume relative to the 65-day Moving Average: GTBIF: 115% vs. ORGO: 55%
Market capitalization -- GTBIF: $1.98B vs. ORGO: $600.04M
GTBIF [@Pharmaceuticals: Generic] is valued at $1.98B. ORGO’s [@Pharmaceuticals: Generic] market capitalization is $600.04M. The market cap for tickers in the [@Pharmaceuticals: Generic] industry ranges from $67.83B to $0. The average market capitalization across the [@Pharmaceuticals: Generic] industry is $3.72B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

GTBIF’s FA Score shows that 1 FA rating(s) are green whileORGO’s FA Score has 1 green FA rating(s).

  • GTBIF’s FA Score: 1 green, 4 red.
  • ORGO’s FA Score: 1 green, 4 red.
According to our system of comparison, both GTBIF and ORGO are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

GTBIF’s TA Score shows that 4 TA indicator(s) are bullish while ORGO’s TA Score has 4 bullish TA indicator(s).

  • GTBIF’s TA Score: 4 bullish, 4 bearish.
  • ORGO’s TA Score: 4 bullish, 5 bearish.
According to our system of comparison, GTBIF is a better buy in the short-term than ORGO.

Price Growth

GTBIF (@Pharmaceuticals: Generic) experienced а +23.64% price change this week, while ORGO (@Pharmaceuticals: Generic) price change was +3.98% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Generic industry was +6.26%. For the same industry, the average monthly price growth was +68.76%, and the average quarterly price growth was +80.82%.

Reported Earning Dates

ORGO is expected to report earnings on Nov 05, 2025.

Industries' Descriptions

@Pharmaceuticals: Generic (+6.26% weekly)

A generic drug contains the same chemical substance as a drug that was originally protected by patents. Generic drugs are generally sold at cheaper price points, compared to name-brand pharmaceuticals, after patents for the more expensive drugs lapse. The generic drug industry has created a major market, thanks to the lower pricing. According to the Center for Justice and Democracy at New York Law School, 80 percent of all drugs prescribed are generic, and generic drugs are chosen 94 percent of the time when they are available. But their manufacturers must be able to prove to the FDA that they can be effective substitutes for the original drugs. Some of the major generic drug makers include Zoetis, Inc., Allergan plc and Mylan N.V.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
GTBIF($1.98B) has a higher market cap than ORGO($596M). GTBIF has higher P/E ratio than ORGO: GTBIF (78.45) vs ORGO (63.75). ORGO YTD gains are higher at: 46.875 vs. GTBIF (5.630). GTBIF has higher annual earnings (EBITDA): 368M vs. ORGO (-274K). GTBIF has more cash in the bank: 211M vs. ORGO (110M). ORGO has less debt than GTBIF: ORGO (42.6M) vs GTBIF (526M). GTBIF has higher revenues than ORGO: GTBIF (1.14B) vs ORGO (459M).
GTBIFORGOGTBIF / ORGO
Capitalization1.98B596M333%
EBITDA368M-274K-134,307%
Gain YTD5.63046.87512%
P/E Ratio78.4563.75123%
Revenue1.14B459M249%
Total Cash211M110M192%
Total Debt526M42.6M1,235%
FUNDAMENTALS RATINGS
GTBIF vs ORGO: Fundamental Ratings
GTBIF
ORGO
OUTLOOK RATING
1..100
1480
VALUATION
overvalued / fair valued / undervalued
1..100
84
Overvalued
77
Overvalued
PROFIT vs RISK RATING
1..100
10095
SMR RATING
1..100
8893
PRICE GROWTH RATING
1..100
3838
P/E GROWTH RATING
1..100
911
SEASONALITY SCORE
1..100
50n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

ORGO's Valuation (77) in the Financial Conglomerates industry is in the same range as GTBIF (84) in the null industry. This means that ORGO’s stock grew similarly to GTBIF’s over the last 12 months.

ORGO's Profit vs Risk Rating (95) in the Financial Conglomerates industry is in the same range as GTBIF (100) in the null industry. This means that ORGO’s stock grew similarly to GTBIF’s over the last 12 months.

GTBIF's SMR Rating (88) in the null industry is in the same range as ORGO (93) in the Financial Conglomerates industry. This means that GTBIF’s stock grew similarly to ORGO’s over the last 12 months.

GTBIF's Price Growth Rating (38) in the null industry is in the same range as ORGO (38) in the Financial Conglomerates industry. This means that GTBIF’s stock grew similarly to ORGO’s over the last 12 months.

GTBIF's P/E Growth Rating (9) in the null industry is in the same range as ORGO (11) in the Financial Conglomerates industry. This means that GTBIF’s stock grew similarly to ORGO’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
GTBIFORGO
RSI
ODDS (%)
Bearish Trend 3 days ago
90%
Bearish Trend 3 days ago
78%
Stochastic
ODDS (%)
Bearish Trend 3 days ago
80%
Bearish Trend 3 days ago
87%
Momentum
ODDS (%)
Bullish Trend 3 days ago
72%
Bullish Trend 3 days ago
80%
MACD
ODDS (%)
Bullish Trend 3 days ago
79%
Bearish Trend 3 days ago
80%
TrendWeek
ODDS (%)
Bullish Trend 3 days ago
78%
Bullish Trend 3 days ago
81%
TrendMonth
ODDS (%)
Bullish Trend 3 days ago
81%
Bullish Trend 3 days ago
80%
Advances
ODDS (%)
Bullish Trend 6 days ago
82%
Bullish Trend 4 days ago
79%
Declines
ODDS (%)
Bearish Trend 11 days ago
85%
Bearish Trend 11 days ago
87%
BollingerBands
ODDS (%)
Bearish Trend 3 days ago
86%
Bearish Trend 3 days ago
88%
Aroon
ODDS (%)
Bullish Trend 3 days ago
82%
Bullish Trend 3 days ago
88%
View a ticker or compare two or three
Interact to see
Advertisement
GTBIF
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
ORGO
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
MPDRX11.310.03
+0.27%
MassMutual Disciplined Gr R3
TCLCX22.54-0.01
-0.04%
Nuveen Large Cap Value A
PPYAX8.90-0.02
-0.22%
PIMCO RAE International A
ATEYX167.94-1.25
-0.74%
AB Sustainable Global Thematic Advisor
CUSIX14.19-0.15
-1.05%
Cullen Small Cap Value I

GTBIF and

Correlation & Price change

A.I.dvisor indicates that over the last year, GTBIF has been closely correlated with CURLF. These tickers have moved in lockstep 82% of the time. This A.I.-generated data suggests there is a high statistical probability that if GTBIF jumps, then CURLF could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To GTBIF
1D Price
Change %
GTBIF100%
-3.79%
CURLF - GTBIF
82%
Closely correlated
-4.66%
TCNNF - GTBIF
82%
Closely correlated
-9.94%
VRNOF - GTBIF
79%
Closely correlated
+2.04%
TSNDF - GTBIF
77%
Closely correlated
-7.85%
CRLBF - GTBIF
71%
Closely correlated
-10.76%
More

ORGO and

Correlation & Price change

A.I.dvisor indicates that over the last year, ORGO has been loosely correlated with PRGO. These tickers have moved in lockstep 47% of the time. This A.I.-generated data suggests there is some statistical probability that if ORGO jumps, then PRGO could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ORGO
1D Price
Change %
ORGO100%
-4.28%
PRGO - ORGO
47%
Loosely correlated
-2.66%
ANIP - ORGO
45%
Loosely correlated
+1.42%
ANIK - ORGO
33%
Poorly correlated
-4.85%
AMRX - ORGO
31%
Poorly correlated
-0.11%
GTBIF - ORGO
29%
Poorly correlated
-3.79%
More